Chembio Diagnostics competitors

Accredited public company director. Dynamic, creative, growth and success oriented leader. Proven experience building and leading an organization from distress to profitability while increasing shareholder value 5x in 24 months.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Mark Leuchtenberger is a Board Member at Melinta Therapeutics Inc, Co-Founder at Alvos Therapeutics Inc, and Executive Chairman at Aleta Biotherapeutics and is based in Boston, Massachusetts. He has experience at Bain & Company and has worked as Board Member at Targanta Therapeutics; Chairman at XENETIC BIOSCIENCES, INC.; and Senior Officer at Biogen Idec. Mark works or has worked as BOARD MEMBER at Wake Forest University - WFU and Chairman at MassBio. He studied at Wake Forest University - WFU; Wake Forest University, Yale School of Management; and Yale School of Management between 1985 and 1987.

Highly motivated senior executive with general management experience in both large multi-national companies and small private equity environments in the diagnostic, medical device, pharmaceutical and life science industries. Demonstrated performance excellence in multi-disciplinary leadership roles including operations, marketing, sales, strategic planning, acquisitions and integrations on domestic and international level. Excel at turning around underperforming businesses with a combination of strong business acumen, outstanding leadership, customer relationships, and superior commercial execution. Dynamic leader with ability to build high performing teams and cross functional collaboration, align and inspire organizations towards a clear vision, and execute for sustainable results.

Dennis Eastburn is a Chief Executive Officer, Co-founder at Barrier Biopharma, Inc. and is based in San Francisco, California. He has worked as Postdoctoral Fellow at University of California San Francisco; Consultant at ARDELYX, INC.; and Chief Scientific Officer, Co-founder at Mission Bio. Dennis studied at The University of Texas at Austin between 1993 and 1997 and University of Colorado Boulder between 1998 and 2004.

Robert 'Rob' Spignesi is a Chief Executive Officer at Rapid Micro Biosystems and Board Member at Rapid Micro Biosystems and is based in Greater Boston. He has worked as VP/Gen Mgr:Americas at Thermo Fisher Scientific, Exec VP:Operations at McKesson, and Aviation Officer at United States Army. Robert attended Columbia University, DOD DOA United States Military Academy, and Columbia Business School between 1996 and 1998.